CRSP CRISPR Therapeutics AG

Price (delayed)

$117.42

Market cap

$8.95B

P/E Ratio

20.75

Dividend/share

N/A

EPS

$5.66

Enterprise value

$7.47B

CRISPR Therapeutics is a leading gene editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene editing technology that ...

Highlights
The equity has soared by 186% YoY and by 44% QoQ
CRSP's quick ratio has soared by 104% YoY and by 19% QoQ

Key stats

What are the main financial stats of CRSP
Market
Shares outstanding
76.2M
Market cap
$8.95B
Enterprise value
$7.47B
Valuations
Price to earnings (P/E)
20.75
Price to book (P/B)
3.42
Price to sales (P/S)
9.87
EV/EBIT
16.56
EV/EBITDA
16.16
EV/Sales
8.29
Earnings
Revenue
$901.76M
EBIT
$451.36M
EBITDA
$462.62M
Free cash flow
$502.19M
Per share
EPS
$5.66
Free cash flow per share
$6.62
Book value per share
$34.36
Revenue per share
$11.89
TBVPS
$38.24
Balance sheet
Total assets
$2.9B
Total liabilities
$295.72M
Debt
$191.2M
Equity
$2.6B
Working capital
$2.52B
Liquidity
Debt to equity
0.07
Current ratio
26.23
Quick ratio
26.1
Net debt/EBITDA
-3.19
Margins
EBITDA margin
51.3%
Gross margin
100%
Net margin
49.5%
Operating margin
49.7%
Efficiency
Return on assets
21.9%
Return on equity
24.1%
Return on invested capital
57.9%
Return on capital employed
16.1%
Return on sales
50.1%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

CRSP stock price

How has the CRISPR Therapeutics AG stock price performed over time
Intraday
0.14%
1 week
-3.33%
1 month
-4.19%
1 year
37.12%
YTD
-23.31%
QTD
-27.47%

Financial performance

How have CRISPR Therapeutics AG's revenue and profit performed over time
Revenue
$901.76M
Gross profit
$901.76M
Operating income
$447.92M
Net income
$446.58M
Gross margin
100%
Net margin
49.5%
The operating margin has surged by 100% since the previous quarter
The net margin has surged by 100% since the previous quarter

Growth

What is CRISPR Therapeutics AG's growth rate over time

Valuation

What is CRISPR Therapeutics AG stock price valuation
P/E
20.75
P/B
3.42
P/S
9.87
EV/EBIT
16.56
EV/EBITDA
16.16
EV/Sales
8.29
The equity has soared by 186% YoY and by 44% QoQ
The price to book (P/B) is 34% lower than the last 4 quarters average of 5.2 and 32% lower than the 5-year quarterly average of 5.0
The price to sales (P/S) is 100% lower than the last 4 quarters average of 5608.6 and 99% lower than the 5-year quarterly average of 1379.1

Efficiency

How efficient is CRISPR Therapeutics AG business performance
The company's return on assets has surged by 188% QoQ
The ROE has soared by 188% from the previous quarter
The ROIC has soared by 169% QoQ and by 139% YoY
The return on sales has surged by 100% since the previous quarter

Dividends

What is CRSP's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for CRSP.

Financial health

How did CRISPR Therapeutics AG financials performed over time
CRISPR Therapeutics AG's total assets has soared by 177% YoY and by 48% from the previous quarter
The total liabilities has surged by 118% year-on-year and by 94% since the previous quarter
The debt is 93% smaller than the equity
The equity has soared by 186% YoY and by 44% QoQ
CRSP's debt to equity has soared by 133% QoQ and by 17% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.